← Back to Search

Exercise for Breast Cancer Survivors

N/A
Recruiting
Led By Christina Dieli-Conwright, PhD, MPH
Research Sponsored by Dana-Farber Cancer Institute
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control or abstinence) prior to study entry and for six months following duration of study participation
Women newly diagnosed (Stage I-III) breast cancer
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 16 weeks
Awards & highlights

Study Summary

This trial will test whether exercise can help Latina breast cancer survivors by improving fitness and reducing risks for heart disease, diabetes, and obesity.

Who is the study for?
This trial is for Latina breast cancer survivors who are obese, have completed their main cancer treatments within the last year, and currently exercise less than 60 minutes a week. They must not smoke, be free from serious chronic diseases, agree to use contraception if applicable, and be willing to travel for the study.Check my eligibility
What is being tested?
The study tests whether Progressive Combined Training (PCT), an exercise program, can improve fitness and reduce heart disease, diabetes, and obesity risks compared to standard care (Attention Control) in participants.See study design
What are the potential side effects?
While specific side effects aren't listed for this type of physical activity intervention, typical concerns might include muscle soreness or strain. The trial will monitor for any adverse reactions related to increased physical activity.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I agree to use effective birth control or abstain from sex for six months during the study.
Select...
I am a woman with newly diagnosed Stage I-III breast cancer.
Select...
I am over 18 years old.
Select...
My breast cancer is in remission with no signs of disease.
Select...
I have had surgery to remove a breast lump or the entire breast.
Select...
I do not have chronic diseases like uncontrolled diabetes, high blood pressure, or thyroid issues.
Select...
I can start an exercise program without heart, lung, or joint issues stopping me.
Select...
I am obese with a BMI over 30, body fat over 30%, and waist size over 35 inches.
Select...
I have not lost more than 10% of my weight in the last 6 months.
Select...
I do not plan to have reconstructive surgery with flap repair during the trial.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~16 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and 16 weeks for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Change in Metabolic Dysregulation (MetD) After Completion of Phase 1 Progressive Combine Training (PCT) -Insulin Resistance
Change in Metabolic Dysregulation (MetD) After Completion of Phase 1 Progressive Combine Training (PCT) -Visceral adiposity
Change in Metabolic Dysregulation (MetD) After Completion of Phase 1 Progressive Combine Training (PCT) -metabolic syndrome (MSY)
Secondary outcome measures
Compare Metabolic Dysregulation (MetD) in Progressive Combine Training (PCT) and Attention (AC) groups - Visceral adiposity
Compare Metabolic Dysregulation (MetD) in Progressive Combine Training (PCT) and Attention (AC) groups - metabolic syndrome (MSY)
Compare Metabolic Dysregulation (MetD) in Progressive Combine Training (PCT) and Attention (AC) groups -Insulin Resistance
+3 more

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: Progressive combine training (PCT)Experimental Treatment1 Intervention
Participants will be randomly assigned to Progressive combine training (PCT) group. Participants will have two (2) baseline tests, then begin a two phase PCT program. Phase 1: Supervised 16-week resistance and cardiovascular exercise at a local YMCA (months 1-4) or remotely at home via Zoom Participants will receive midpoint testing, approximately week 8. Phase 2: Unsupervised 16-week resistance and cardiovascular exercise at a local YMCA (months 5-8) or remotely at home Participants will receive midpoint testing, approximately two months into phase 2. After the two (2) 16-week phases, participants will be followed for 4 months.
Group II: Attention Control (AC)Active Control1 Intervention
Participants will be randomly assigned to Attention Control (AC) group. Two (2) baseline tests will be performed prior to starting the program. Participants will perform 12 months of home-based stretching and have a 1x test performed during months 2, 4, 6, 8 and 10. Two (2) tests will be performed in month 12.

Find a Location

Who is running the clinical trial?

American Cancer Society, Inc.OTHER
224 Previous Clinical Trials
110,295 Total Patients Enrolled
32 Trials studying Breast Cancer
8,724 Patients Enrolled for Breast Cancer
Dana-Farber Cancer InstituteLead Sponsor
1,081 Previous Clinical Trials
340,822 Total Patients Enrolled
142 Trials studying Breast Cancer
22,532 Patients Enrolled for Breast Cancer
Christina Dieli-Conwright, PhD, MPHPrincipal InvestigatorDana-Farber Cancer Institute
3 Previous Clinical Trials
195 Total Patients Enrolled
1 Trials studying Breast Cancer
135 Patients Enrolled for Breast Cancer

Media Library

Progressive Combine Training (PCT) Clinical Trial Eligibility Overview. Trial Name: NCT04717050 — N/A
Breast Cancer Research Study Groups: Progressive combine training (PCT), Attention Control (AC)
Breast Cancer Clinical Trial 2023: Progressive Combine Training (PCT) Highlights & Side Effects. Trial Name: NCT04717050 — N/A
Progressive Combine Training (PCT) 2023 Treatment Timeline for Medical Study. Trial Name: NCT04717050 — N/A
~42 spots leftby Jun 2025